
Opinion|Videos|July 1, 2024
RSV: Risk Factors and How It’s Spread
A panel of experts outline who’s at risk for RSV and how it’s spread, highlighting how transmission can be minimized.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Who is at risk for respiratory syncytial virus (RSV) and how prevalent is RSV among older adults?
- What is the mortality rate associated with RSV infections?
- How is RSV spread and what are the typical symptoms for RSV?
- How can infected people minimize the spread of RSV?
- How can infected people minimize the spread of RSV?
Advertisement
Related to this article

Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.

Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.

Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.

In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.

Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5


